Anti-PAX8 antibody

Overview
- PAX‐8 is expressed in the thyroid, non‐ciliated mucosal cells of the fallopian tubes and simple ovarian inclusion cysts, but not normal ovarian surface epithelial cells. PAX‐8 is expressed in ovarian serous, endometrioid, and clear cell carcinomas, but only rarely in primary ovarian mucinous adenocarcinomas. Over 98% of clear cell RCCs, 90% of papillary RCCs, and 95% of oncocytomas were positive for PAX‐8. Similarly, the absence of expression of PAX‐8 in breast and other non‐GYN carcinomas other than those primary to the thyroid indicates that PAX‐8 is an important new marker of ovarian cancer and a useful marker for the differential diagnoses in lung and neck tumors, or tumors at distant sites where primary lung carcinoma or thyroid carcinoma are possibilities. PAX‐8, combined with organ system‐specific markers such as uroplakin, mammaglobin, and TTF‐1 can be a very useful panel to determine the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast. Unlike the polyclonal anti‐PAX‐8 antibody, the ZR1 rabbit monoclonal antibody does not react with pancreatic neuroendocrine tumors, thymic tumors, and lymphocytes.
  
  Please contact us at for specific academic pricing.
  
  More Details
  
  ST John's Labs
Properties
- Host
  
  rabbit
  
  Antibody Type
  
  monoclonal
  
  Isotype
  
  IgG
  
  Reactivity
  
  human
  
  Clone
  
  ZR1
  
  Immunogen
  
  Synthetic peptide corresponding to the C‐ terminus of Human PAX8 protein
  
  Conjugate
  
  Unconjugated
  
  Formulation
  
  Purified antibody diluted in Tris‐HCI buffer containing stabilizing protein and <0.1% sodium azide.
  
  Storage
  
  Store at 2-8°C for up to 1 year
  
  Regulatory Status
  
  RUO
  
  * For research use only